QUZYTTIR

Peak

cetirizine hydrochloride

NDAINTRAVENOUSSOLUTION
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3

Clinical Trials (3)

NCT04189588Phase 2Completed

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

Started Mar 2020
34 enrolled
Oncology Patients Receiving Chemotherapy
NCT00881127Phase 1Completed

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions

Started Jul 2005
40 enrolled
Allergies
NCT00881634Phase 1Completed

To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fed Conditions

Started Jun 2005
40 enrolled
Allergies

Loss of Exclusivity

LOE Date
Feb 28, 2030
48 months away
Patent Expiry
Feb 28, 2030

Patent Records (5)

Patent #ExpiryTypeUse Code
8513259
Feb 11, 2030
U-2636
9119771
Feb 11, 2030
U-2635
9180090
Feb 11, 2030
U-2635
8263581
Feb 28, 2030
U-2635
8314083
Feb 28, 2030
U-2634
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers